SXL
GRCE

Summit X LLC’s Grace Therapeutics GRCE Stock Holding History

Summit X LLC’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-521
Closed – – 452
2020
Q3 		$0 Buy
+521
New +$13.5K ﹤0.01% 452

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit X LLC's GRCE Position: Q4 2020 in Review

Summit X LLC sold out of Grace Therapeutics (GRCE) in Q4 2020, closing a stake of 521 shares.

Summit X LLC first reported a position in GRCE in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 28 funds tracked by Wall St. Rank hold GRCE as of Q4 2020.

  • Summit X LLC reported no remaining Grace Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Summit X LLC sold 521 Grace Therapeutics shares in Q4 2020.
  • Summit X LLC first reported a position in Grace Therapeutics in Q3 2020 and held it in 1 quarter.
  • Summit X LLC's Grace Therapeutics position peaked at $0 in Q3 2020.
  • 28 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2020.

Based on Summit X LLC's 13F filing for Q4 2020, filed 29 Jan 2021.